Drugs / APN-1607
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05005819 | May 2021 → Jan 2024 | progressive supranuclear palsy | Invicro | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APN-1607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05005819 ↗ |
| Modality | Diagnostic / imaging agent | “evaluate \[18F\]APN-1607 as a PET radiotracer” NCT05005819 ↗ |
| Route | Intravenous | “Participants will receive an IV bolus injection of \[18F\]APN-1607” NCT05005819 ↗ |